Logo image of CSTE

CAESARSTONE LTD (CSTE) Stock Fundamental Analysis

NASDAQ:CSTE - Nasdaq - IL0011259137 - Common Stock - Currency: USD

3.27  -0.09 (-2.68%)

After market: 3.27 0 (0%)

Fundamental Rating

3

Overall CSTE gets a fundamental rating of 3 out of 10. We evaluated CSTE against 40 industry peers in the Building Products industry. The financial health of CSTE is average, but there are quite some concerns on its profitability. CSTE has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year CSTE has reported negative net income.
CSTE had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: CSTE reported negative net income in multiple years.
CSTE had a positive operating cash flow in 4 of the past 5 years.
CSTE Yearly Net Income VS EBIT VS OCF VS FCFCSTE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M -100M

1.2 Ratios

CSTE has a Return On Assets of -7.11%. This is amonst the worse of the industry: CSTE underperforms 85.00% of its industry peers.
CSTE has a worse Return On Equity (-14.09%) than 82.50% of its industry peers.
Industry RankSector Rank
ROA -7.11%
ROE -14.09%
ROIC N/A
ROA(3y)-11.12%
ROA(5y)-6.06%
ROE(3y)-20.4%
ROE(5y)-11.19%
ROIC(3y)N/A
ROIC(5y)N/A
CSTE Yearly ROA, ROE, ROICCSTE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 -20 -30

1.3 Margins

With a Gross Margin value of 21.81%, CSTE is not doing good in the industry: 77.50% of the companies in the same industry are doing better.
CSTE's Gross Margin has declined in the last couple of years.
CSTE does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 21.81%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-6.44%
GM growth 5Y-4.33%
CSTE Yearly Profit, Operating, Gross MarginsCSTE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 20 30 40

More info and screens

6

2. Health

2.1 Basic Checks

CSTE does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CSTE has about the same amount of shares outstanding.
CSTE has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, CSTE has an improved debt to assets ratio.
CSTE Yearly Shares OutstandingCSTE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
CSTE Yearly Total Debt VS Total AssetsCSTE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

CSTE has an Altman-Z score of 1.70. This is a bad value and indicates that CSTE is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of 1.70, CSTE is not doing good in the industry: 87.50% of the companies in the same industry are doing better.
The Debt to FCF ratio of CSTE is 0.24, which is an excellent value as it means it would take CSTE, only 0.24 years of fcf income to pay off all of its debts.
CSTE's Debt to FCF ratio of 0.24 is amongst the best of the industry. CSTE outperforms 90.00% of its industry peers.
A Debt/Equity ratio of 0.00 indicates that CSTE is not too dependend on debt financing.
CSTE's Debt to Equity ratio of 0.00 is amongst the best of the industry. CSTE outperforms 85.00% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0.24
Altman-Z 1.7
ROIC/WACCN/A
WACC8.97%
CSTE Yearly LT Debt VS Equity VS FCFCSTE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M 400M

2.3 Liquidity

A Current Ratio of 2.30 indicates that CSTE has no problem at all paying its short term obligations.
CSTE has a Current ratio of 2.30. This is comparable to the rest of the industry: CSTE outperforms 57.50% of its industry peers.
CSTE has a Quick Ratio of 1.55. This is a normal value and indicates that CSTE is financially healthy and should not expect problems in meeting its short term obligations.
CSTE has a Quick ratio (1.55) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 2.3
Quick Ratio 1.55
CSTE Yearly Current Assets VS Current LiabilitesCSTE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 35.82% over the past year.
CSTE shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -21.59%.
Measured over the past years, CSTE shows a decrease in Revenue. The Revenue has been decreasing by -4.09% on average per year.
EPS 1Y (TTM)35.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-25%
Revenue 1Y (TTM)-21.59%
Revenue growth 3Y-11.71%
Revenue growth 5Y-4.09%
Sales Q2Q%-23.86%

3.2 Future

The Earnings Per Share is expected to grow by 30.52% on average over the next years. This is a very strong growth
CSTE is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 3.68% yearly.
EPS Next Y40.7%
EPS Next 2Y30.52%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year2.64%
Revenue Next 2Y3.68%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
CSTE Yearly Revenue VS EstimatesCSTE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 200M 400M 600M
CSTE Yearly EPS VS EstimatesCSTE Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 1 -1 2

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CSTE. In the last year negative earnings were reported.
Also next year CSTE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CSTE Price Earnings VS Forward Price EarningsCSTE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Compared to the rest of the industry, the Price/Free Cash Flow ratio of CSTE indicates a rather cheap valuation: CSTE is cheaper than 100.00% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 5.27
EV/EBITDA N/A
CSTE Per share dataCSTE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8 10

4.3 Compensation for Growth

CSTE's earnings are expected to grow with 30.52% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y30.52%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CSTE!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CAESARSTONE LTD

NASDAQ:CSTE (3/7/2025, 8:16:30 PM)

After market: 3.27 0 (0%)

3.27

-0.09 (-2.68%)

Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupCapital Goods
GICS IndustryBuilding Products
Earnings (Last)03-05 2025-03-05/bmo
Earnings (Next)05-06 2025-05-06/bmo
Inst Owners37.16%
Inst Owner Change0.03%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap113.01M
Analysts82.86
Price Target5.1 (55.96%)
Short Float %0.94%
Short Ratio5.22
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-43.8%
Min EPS beat(2)-49.19%
Max EPS beat(2)-38.41%
EPS beat(4)2
Avg EPS beat(4)-15.48%
Min EPS beat(4)-49.19%
Max EPS beat(4)20.34%
EPS beat(8)2
Avg EPS beat(8)-311.78%
EPS beat(12)3
Avg EPS beat(12)-229.38%
EPS beat(16)6
Avg EPS beat(16)-141.91%
Revenue beat(2)0
Avg Revenue beat(2)-7.62%
Min Revenue beat(2)-11.77%
Max Revenue beat(2)-3.48%
Revenue beat(4)0
Avg Revenue beat(4)-7.48%
Min Revenue beat(4)-11.77%
Max Revenue beat(4)-3.48%
Revenue beat(8)1
Avg Revenue beat(8)-7.53%
Revenue beat(12)1
Avg Revenue beat(12)-6%
Revenue beat(16)4
Avg Revenue beat(16)-3.08%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.25
P/FCF 5.27
P/OCF 3.55
P/B 0.41
P/tB 0.41
EV/EBITDA N/A
EPS(TTM)-0.86
EYN/A
EPS(NY)-0.51
Fwd EYN/A
FCF(TTM)0.62
FCFY18.98%
OCF(TTM)0.92
OCFY28.2%
SpS12.82
BVpS8.02
TBVpS8.01
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -7.11%
ROE -14.09%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 21.81%
FCFM 4.84%
ROA(3y)-11.12%
ROA(5y)-6.06%
ROE(3y)-20.4%
ROE(5y)-11.19%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-6.44%
GM growth 5Y-4.33%
F-Score5
Asset Turnover0.81
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0.24
Debt/EBITDA N/A
Cap/Depr 60.82%
Cap/Sales 2.35%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.3
Quick Ratio 1.55
Altman-Z 1.7
F-Score5
WACC8.97%
ROIC/WACCN/A
Cap/Depr(3y)49.02%
Cap/Depr(5y)60.64%
Cap/Sales(3y)2.3%
Cap/Sales(5y)3.17%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)35.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-25%
EPS Next Y40.7%
EPS Next 2Y30.52%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-21.59%
Revenue growth 3Y-11.71%
Revenue growth 5Y-4.09%
Sales Q2Q%-23.86%
Revenue Next Year2.64%
Revenue Next 2Y3.68%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y24.92%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year76.33%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-61.25%
FCF growth 3YN/A
FCF growth 5Y-18.43%
OCF growth 1Y-52.09%
OCF growth 3Y15.48%
OCF growth 5Y-17.42%